Format

Send to

Choose Destination
Clin Infect Dis. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26.

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Author information

1
HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco.
2
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
3
Fundacao Oswaldo Cruz, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil.
4
IMPACTA, Lima, Peru.
5
Joint Clinical Research Center, Kampala, Uganda.
6
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.
7
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa.
8
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.

Abstract

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.

KEYWORDS:

HIV/AIDS; efavirenz; pharmacogenetic; rifampin; tuberculosis

PMID:
25722197
PMCID:
PMC4542662
DOI:
10.1093/cid/civ155
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center